Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recursion Pharmaceuticals ...
Cash Balance: Ended the year with $754 million in cash. Operating Expenses: 35% reduction in pro forma operating expenses year over year. 2026 Cash Operating Expenses: Expected to be under $390 ...
Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...
Recursion Pharmaceuticals’s stock price closed at $3.53. It is down -23.76% in the last 3 months and down -57.67% in the last 12 months. Recursion Pharmaceuticals saw 3 positive EPS revisions and 1 ...
Abstract: Complicated deformation problems are frequently encountered in medical image registration tasks. Although various advanced registration models have been proposed, accurate and efficient ...
Abstract: This paper studies the estimation of dynamic route choice behavior of drivers with incomplete fixed location-based sensor data, such as radio frequency identification (RFID) data. Unlike ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Over 21 days of talking with ChatGPT, an otherwise perfectly sane man became convinced that he was a real-life superhero. We analyzed the conversation. By Kashmir Hill and Dylan Freedman Kashmir Hill ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results